Preclinical characterization of CNS-penetrant BRAF class I/II/III mutation inhibitor BDTX-4933

Nov. 14, 2022

Researchers from Black Diamond Therapeutics Inc. presented the discovery and preclinical characterization of a novel brain-penetrant BRAF class I/II/III mutation inhibitor, BDTX-4933.

BioWorld Science Conferences Cancer

Today's news in brief

BioWorld

BioWorld briefs for Nov. 7, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Nov. 7, 2025.

Photo of a red fox head in the shadows with a black background,

Enara validates first dark antigen cancer target, unveils bispecific T-cell engager

BioWorld

Enara Bio Ltd. is staking a claim to having validated the first in a new class of tumor antigens derived from unannotated regions of the dark genome, describing...

Ulipristal reprograms breast tissue, cutting cancer-prone cells

BioWorld

Blocking progesterone receptor (PR) activity has long been viewed as a possible approach to breast cancer prevention. Historically, most supporting evidence came...

Mwyngil Therapeutics in-licenses GPR75 modulators

BioWorld Science

Mwyngil Therapeutics Inc. has in-licensed several lead GPR75 modulator molecules and a proprietary cell-surface discovery platform from Expert Systems Inc.